ScienceAlert on MSN

Experimental Drug Stops 90% of Pancreatic Cancer Cell Spread in Lab Tests

The pancreas is in the upper part of the abdomen. (Sebastian Kaulitzki/Science Photo Library/Getty Images) Pancreatic ductal ...
Multiple Sclerosis News Today

Variant tied to severe MS may affect cognition in healthy adults

A gene variant tied to more severe MS disability may also correlate with poor cognitive performance in healthy adults, per a ...
SHARK BYTES on MSN

When the US government began testing nuclear weapons on the island, they accidentally created a monster shark

This video investigates whether nuclear testing at Bikini Atoll may have affected sharks living there decades later. The ...

Roche KRAS drug succeeds in head-to-head lung cancer study

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...

A Two-Antibody Cocktail Targets Two Of The World’s Deadliest Viruses

A two-antibody cocktail that targets Nipah and Hendra’s receptor-binding and fusion proteins protects animals from lethal ...

My father died of cancer at 72. A $12,000 longevity exam at a Silicon Valley clinic found both good and bad news in my DNA.

I enrolled in Human Longevity's executive health program. My cancer results were reassuring, but my genetic results left me a ...

Kidney Cancer Genetic Factors: Doctor Explains Who Is At A Higher Risk

Kidney cancer is among the ten most common cancers worldwide, with its incidence steadily rising due to ageing populations, ...
Anadolu Agency

Roche announces successful pivotal trial for experimental lung cancer drug

Swiss pharmaceutical and diagnostics company Roche announced Thursday that its experimental lung cancer treatment divarasib ...

EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia

For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab ...
The Manila Times

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung ...

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in ...

For creative night owls, the 9-to-5 is pointless

Most offices run on a 9-to-5 schedule, or one that closely resembles it. But being clocked in doesn’t mean you’re locked in. ...